Search company, investor...

ENTRA Pharmaceuticals

entrapharma.com

Stage

Series A | Alive

Total Raised

$4.2M

Last Raised

$4.2M | 14 yrs ago

About ENTRA Pharmaceuticals

ENTRA Pharmaceuticals is a specialty pharmaceutical company developing therapies and improving existing treatments in areas with high unmet medical needs. In addition to the company's technology platform, ENTRA possesses strong expertise in preclinical and clinical drug development and commercialization.

Headquarters Location

Boston, Massachusetts, 02101,

United States

Missing: ENTRA Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ENTRA Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ENTRA Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ENTRA Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

ENTRA Pharmaceuticals Patents

ENTRA Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/28/2008

11/9/2010

Drug delivery devices, Dosage forms, Medical equipment, Actuators, Pharmacokinetics

Grant

Application Date

7/28/2008

Grant Date

11/9/2010

Title

Related Topics

Drug delivery devices, Dosage forms, Medical equipment, Actuators, Pharmacokinetics

Status

Grant

ENTRA Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is ENTRA Pharmaceuticals's headquarters?

    ENTRA Pharmaceuticals's headquarters is located at Boston.

  • What is ENTRA Pharmaceuticals's latest funding round?

    ENTRA Pharmaceuticals's latest funding round is Series A.

  • How much did ENTRA Pharmaceuticals raise?

    ENTRA Pharmaceuticals raised a total of $4.2M.

  • Who are the investors of ENTRA Pharmaceuticals?

    Investors of ENTRA Pharmaceuticals include North Bridge Venture Partners, Flybridge Capital Partners and Boston University Technology Development.

  • Who are ENTRA Pharmaceuticals's competitors?

    Competitors of ENTRA Pharmaceuticals include CytImmune Sciences, Charleston Laboratories, Aegerion Pharmaceuticals, Glaukos, PrevaCept Infection Control, Napo Pharmaceuticals, Combinent BioMedical Systems, Sequel Pharmaceuticals, Nps Pharmaceuticals, Omthera Pharmaceuticals and 13 more.

Compare ENTRA Pharmaceuticals to Competitors

I
IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

A
Advent Pharmaceuticals

Advent Pharmaceuticals is a specialty pharmaceutical company focused on developing inhaled drug products using a dry powder inhalation delivery system. The products are mostly used for the treatment of asthma and other respiratory diseases.

K
Kytogenics Pharmaceuticals Limited

Kytogenics is a medical device company. It had developed the Nocc Hydrophilic Wound Dressing.Kytogenics Pharmaceuticals, Inc. is a biomedical company engaged in the development of products based on its medical device and drug delivery patented platform technology.

C
CNSBio

Relevare Pharmaceuticals, formerly CNSBio, is a specialty pharmaceutical company focused on the development of novel therapies to treat chronic and acute pain. Relevare Pharmaceuticals exciting clinical-stage pipeline is comprised of programs that combine or reposition drugs known to be active at CNS targets that modulate pain perception and transmission, and for which there is strong safety evidence in humans. In April 2010, CNSBio rebranded to Relevare Pharmaceuticals.

A
AkaRx

AkaRx develops therapeutic products including avatrombopag, which is an investigational oral thrombopoietin receptor agonist.

S
SoluBest

SoluBest is a clinical stage pharmaceutical company developing nanoformulations of existing therapeutic medicines in several fields. Solubest uses its advanced polymer formulations to prepare nano-particles of drugs with delivery or compliance insufficiencies. SoluBest's pipeline of existing off-patent drugs are being re-formulated for:nn * its own product developmentn * co-development partners

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.